LEADIANT BIOSCIENCES, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1980-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.leadiant.com
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
7
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
- Conditions
- Cerebrotendinous Xanthomatoses
- Interventions
- Drug: Chenodeoxycholic acid Placebo
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Leadiant Biosciences, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06260748
- Locations
- 🇮🇱
Sheba Medical Center, Tel HaShomer, Israel
Multi-Center Study of ManNAc for GNE Myopathy
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Leadiant Biosciences, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT04231266
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸University of Kansas, Medical Center, Kansas City, Kansas, United States
STP206 for the Prevention of Necrotizing Enterocolitis (NEC)
- Conditions
- Necrotizing Enterocolitis
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Leadiant Biosciences, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT01954017
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Sheridan Clinical Research / Plantation General Hospital, Sunrise, Florida, United States
🇺🇸Augusta University, Augusta, Georgia, United States
EZN-2279 in Patients With ADA-SCID
- Conditions
- Adenosine Deaminase DeficiencyADA-SCIDSevere Combined Immunodeficiency
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Leadiant Biosciences, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01420627
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
Safety and Tolerability of STP206 in Healthy Adult Subjects
- Conditions
- Healthy
- Interventions
- Drug: STP206 or vehicle control
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Leadiant Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00922324
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States